Undisclosed small molecule for autoimmune diseases / Boehringer Ingelheim, Kyowa Kirin - LARVOL DELTA

Boehringer Ingelheim and Kyowa Kirin…announced that Boehringer Ingelheim has licensed a pre-clinical program from Kyowa Kirin to develop a potential first-in-class, small molecule for the treatment of autoimmune diseases (GlobeNewswire) - "Under the terms of the agreement Boehringer Ingelheim will receive exclusive worldwide rights from Kyowa Kirin to develop this small molecule program. Kyowa Kirin is eligible to receive up to € 640 million, including an upfront payment, success-based development, regulatory, and commercial milestone payments, in addition to royalties on possible sales."

Licensing / partnership • Immunology